## **Core Concept**
The question tests understanding of anti-TNF-α agents, specifically their mechanism of action and binding properties to TNF-α. TNF-α (Tumor Necrosis Factor-alpha) is a cytokine involved in systemic inflammation and is a key player in autoimmune diseases. Anti-TNF-α agents are used to treat conditions like rheumatoid arthritis, Crohn's disease, and psoriasis.

## **Why the Correct Answer is Right**
The correct answer, **Etanercept**, is a fusion protein that acts as a decoy receptor for TNF-α, binding to both the soluble and transmembrane-bound forms of TNF-α. This dual binding capability distinguishes it from other anti-TNF-α agents like infliximab and adalimumab, which primarily bind to soluble TNF-α. Etanercept's mechanism involves preventing TNF-α from interacting with its cell surface receptor, thereby inhibiting the inflammatory cascade.

## **Why Each Wrong Option is Incorrect**
- **Option A (Infliximab):** Infliximab is a chimeric monoclonal antibody that primarily binds to soluble TNF-α. It does not have significant binding to the transmembrane form of TNF-α.
- **Option B (Adalimumab):** Adalimumab is a fully human monoclonal antibody that also primarily targets soluble TNF-α. Like infliximab, it does not effectively bind to the transmembrane-bound form.
- **Option D (Certolizumab):** Certolizumab pegol is a pegylated Fab' fragment of a humanized monoclonal antibody that targets TNF-α. It mainly binds to soluble TNF-α and has a different mechanism and structure compared to etanercept.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that etanercept, due to its unique structure as a fusion protein, offers a broader mechanism of action by binding to both soluble and transmembrane TNF-α. This property makes it effective in treating autoimmune diseases but also contributes to its side effect profile, which can include increased risk of infections.

## **Correct Answer: C. Etanercept**